131 related articles for article (PubMed ID: 29074502)
1. EBV latent membrane protein 2A orchestrates p27
Fish K; Sora RP; Schaller SJ; Longnecker R; Ikeda M
Blood; 2017 Dec; 130(23):2516-2526. PubMed ID: 29074502
[TBL] [Abstract][Full Text] [Related]
2. Two Pathways of p27
Sora RP; Ikeda M; Longnecker R
mBio; 2019 Apr; 10(2):. PubMed ID: 30992353
[TBL] [Abstract][Full Text] [Related]
3. p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer.
Zhao H; Lu Z; Bauzon F; Fu H; Cui J; Locker J; Zhu L
Oncogene; 2017 Jan; 36(1):60-70. PubMed ID: 27181203
[TBL] [Abstract][Full Text] [Related]
4. Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignancies.
Kratzat S; Nikolova V; Miething C; Hoellein A; Schoeffmann S; Gorka O; Pietschmann E; Illert AL; Ruland J; Peschel C; Nilsson J; Duyster J; Keller U
PLoS One; 2012; 7(5):e37433. PubMed ID: 22624029
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of Cks1 Leads to Learning and Long-Term Memory Defects and p27 Dependent Formation of Neuronal Cofilin Aggregates.
Kukalev A; Ng YM; Ju L; Saidi A; Lane S; Mondragon A; Dormann D; Walker SE; Grey W; Ho PW; Stephens DN; Carr AM; Lamsa K; Tse E; Yu VPCC
Cereb Cortex; 2017 Jan; 27(1):11-23. PubMed ID: 28365778
[TBL] [Abstract][Full Text] [Related]
6. Interferon-γ-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation.
Bahram F; Hydbring P; Tronnersjö S; Zakaria SM; Frings O; Fahlén S; Nilsson H; Goodwin J; von der Lehr N; Su Y; Lüscher B; Castell A; Larsson LG
Oncotarget; 2016 Jan; 7(3):2837-54. PubMed ID: 26701207
[TBL] [Abstract][Full Text] [Related]
7. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway.
Swart R; Ruf IK; Sample J; Longnecker R
J Virol; 2000 Nov; 74(22):10838-45. PubMed ID: 11044134
[TBL] [Abstract][Full Text] [Related]
8. Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation.
Fukuda M; Kawaguchi Y
J Virol; 2014 May; 88(9):5189-94. PubMed ID: 24554661
[TBL] [Abstract][Full Text] [Related]
9. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
Domostegui A; Peddigari S; Mercer CA; Iannizzotto F; Rodriguez ML; Garcia-Cajide M; Amador V; Diepstraten ST; Kelly GL; Salazar R; Kozma SC; Kusnadi EP; Kang J; Gentilella A; Pearson RB; Thomas G; Pelletier J
Blood; 2021 Jun; 137(24):3351-3364. PubMed ID: 33512431
[TBL] [Abstract][Full Text] [Related]
10. PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein.
Peng M; Wang J; Zhang D; Jin H; Li J; Wu XR; Huang C
Oncogene; 2018 Oct; 37(43):5735-5748. PubMed ID: 29930380
[TBL] [Abstract][Full Text] [Related]
11. A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.
Poe JC; Minard-Colin V; Kountikov EI; Haas KM; Tedder TF
J Immunol; 2012 Sep; 189(5):2318-25. PubMed ID: 22826319
[TBL] [Abstract][Full Text] [Related]
12. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DC; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
Genes Dev; 2014 Jan; 28(1):58-70. PubMed ID: 24395247
[TBL] [Abstract][Full Text] [Related]
13. B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma.
Ruddell A; Harrell MI; Furuya M; Kirschbaum SB; Iritani BM
Neoplasia; 2011 Aug; 13(8):748-57. PubMed ID: 21847366
[TBL] [Abstract][Full Text] [Related]
14. MYC's Fine Line Between B Cell Development and Malignancy.
de Barrios O; Meler A; Parra M
Cells; 2020 Feb; 9(2):. PubMed ID: 32102485
[TBL] [Abstract][Full Text] [Related]
15. Caspase-resistant ROCK1 expression prolongs survival of Eµ-Myc B cell lymphoma mice.
Mardilovich K; Naylor G; Julian L; Phinichkusolchit N; Keeshan K; Blyth K; Olson MF
Dis Model Mech; 2024 May; 17(5):. PubMed ID: 38616733
[TBL] [Abstract][Full Text] [Related]
16. Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway.
Hunter JE; Campbell AE; Hannaway NL; Kerridge S; Luli S; Butterworth JA; Sellier H; Mukherjee R; Dhillon N; Sudhindar PD; Shukla R; Brownridge PJ; Bell HL; Coxhead J; Taylor L; Leary P; Hasoon MSR; Collins I; Garrett MD; Eyers CE; Perkins ND
Biochem J; 2022 Oct; 479(19):2063-2086. PubMed ID: 36240066
[TBL] [Abstract][Full Text] [Related]
17. Insights about MYC and Apoptosis in B-Lymphomagenesis: An Update from Murine Models.
Vecchio E; Fiume G; Correnti S; Romano S; Iaccino E; Mimmi S; Maisano D; Nisticò N; Quinto I
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32549409
[TBL] [Abstract][Full Text] [Related]
18. MYC Oncogene Contributions to Release of Cell Cycle Brakes.
García-Gutiérrez L; Delgado MD; León J
Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30909496
[TBL] [Abstract][Full Text] [Related]
19. Cellular redox homeostasis maintained by malic enzyme 2 is essential for MYC-driven T cell lymphomagenesis.
Li W; Kou J; Zhang Z; Li H; Li L; Du W
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2217869120. PubMed ID: 37253016
[TBL] [Abstract][Full Text] [Related]
20. PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis.
Napoletani G; Soldan SS; Kannan T; Preston-Alp S; Vogel P; Maestri D; Caruso LB; Kossenkov A; Sobotka A; Lieberman PM; Tempera I
bioRxiv; 2023 Jul; ():. PubMed ID: 37461649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
